Greenwich LifeSciences, Inc. (NASDAQ: GLSI) provided an update on its Phase 3 FLAMINGO-01 trial evaluating GLSI-100, an immunotherapy designed to prevent breast cancer recurrence. The company announced that the study's Data Safety Monitoring Board (DSMB) recommended the trial continue without modification following its May 2026 review. This recommendation is a critical milestone, indicating that the treatment is safe and the trial is progressing as planned.
Regulatory authorities in the United States and Europe have supported planned protocol changes that include expanding enrollment to as many as 2,000 patients. The changes also include increasing enrollment rates by including all HLA types and maintaining enrollment through interim analyses. These modifications are intended to strengthen the study design and increase the probability of success, potentially accelerating the path to market for this promising immunotherapy.
Greenwich LifeSciences reported that more than 1,500 patients have been screened across approximately 170 to 180 clinical sites in 11 countries. The company plans to expand into additional European markets as well as the United Kingdom and Canada, broadening the reach of the trial and enhancing patient diversity. This expansion is crucial for generating robust data that can support regulatory approval in multiple regions.
Preliminary data from the fully enrolled open-label non-HLA-A*02 arm continues to show a 70% to 80% reduction in breast cancer recurrence following the primary immunization series. However, the company emphasized that these findings remain preliminary and are not predictive of the final Phase 3 results. The promising early signals suggest that GLSI-100 could be a significant advancement in preventing breast cancer recurrence, particularly for patients with HER2-positive tumors.
The implications of this announcement are substantial. If the Phase 3 trial confirms the preliminary efficacy, GLSI-100 could offer a new standard of care for breast cancer patients who have undergone surgery, potentially reducing the risk of recurrence and improving long-term outcomes. The expanded study design, including all HLA types, ensures that the treatment is tested in a broader patient population, which could lead to a more inclusive indication upon approval.
For more details, the full press release is available at https://ibn.fm/elLnN. Additional information about Greenwich LifeSciences and the FLAMINGO-01 trial can be found on the company's website at www.greenwichlifesciences.com.
